No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors With 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Icecure Medical Analyst Ratings
IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript Summary
IceCure Medical GAAP EPS of $0.22 , Revenue of $2.41M
Icecure Medical | 6-K: Report of foreign private issuer (related to financial reporting)
Press Release: IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense(R) Cryoablation
Unlock the Full List